The Largest Companies by Market Capitalization, Revenues, Income and Employees within In Vitro & In Vivo Diagnostic Substances Industry
|
| |
Marketcap |
Revenues (TTM) |
Net Income (TTM) |
Employees |
| Company |
(Millions) |
(Millions) |
(Millions) |
Number |
| Idexx Laboratories Inc |
$ 41,539 |
$ 3,931 |
$ 895 |
11,000 |
| Lantheus Holdings Inc |
$ 5,514 |
$ 1,536 |
$ 254 |
834 |
| Quidelortho Corp |
$ 2,348 |
$ 2,765 |
$ -359 |
3,700 |
| Neogen Corporation |
$ 1,360 |
$ 914 |
$ -457 |
1,674 |
| Celldex Therapeutics inc |
$ 1,302 |
$ 8 |
$ -179 |
50 |
| Heska Corporation |
$ 1,247 |
$ 255 |
$ -20 |
610 |
| Intellia Therapeutics Inc |
$ 861 |
$ 46 |
$ -526 |
120 |
| Myriad Genetics Inc |
$ 376 |
$ 830 |
$ -101 |
2,700 |
| Alpha Teknova Inc |
$ 360 |
$ 37 |
$ -23 |
- |
| Cardio Diagnostics Holdings Inc |
$ 145 |
$ 0 |
$ -8 |
55 |
| Achieve Life Sciences Inc |
$ 85 |
- |
$ -40 |
25 |
| Biomerica Inc |
$ 60 |
$ 6 |
$ -6 |
64 |
| Immucell Corp |
$ 41 |
$ 26 |
$ -2 |
50 |
| Volitionrx Limited |
$ 41 |
$ 1 |
$ -27 |
11 |
| Oncocyte Corporation |
$ 36 |
$ 2 |
$ -61 |
46 |
| Nymox Pharmaceutical Corporation |
$ 18 |
$ 0 |
$ -9 |
24 |
| Burzynski Research Institute Inc |
$ 7 |
- |
$ -1 |
- |
| Trinity Biotech Plc |
$ 6 |
$ 57 |
$ -37 |
380 |
| Aspira Women s Health Inc |
$ 1 |
$ 8 |
$ -13 |
66 |
| Tnf Pharmaceuticals Inc |
$ 0 |
- |
$ -24 |
59 |
| Navidea Biopharmaceuticals Inc |
$ 0 |
$ 1 |
$ -1 |
23 |
| Total In Vitro & In Vivo Diagnostic Substances Industry |
$ 55,347 |
$ 10,423 |
$ -745 |
21,491 |
Recent News from The Largest Companies in In Vitro & In Vivo Diagnostic Substances Industry |
|
Clinical Study
Myriad Genetics: Unveiling Clinical Validity of Precise MRD at AACR Annual MeetingIn an era where precision medicine is increasingly guiding therapeutic decisions, Myriad Genetics continues to make impressive strides. The company recently highlighted the clinical validity of its molecular residual disease (MRD) testing platform, Precise MRD?, during a pi...
|
|
|
Clinical Study
In recent weeks, Achieve Life Sciences Inc. has garnered attention following the publication of its Phase 3 ORCA-3 trial results on cytisinicline, a potential new tool for smoking cessation. The findings, published in JAMA Internal Medicine, highlight the drug s ability to significantly increase quit rates and reduce nicotine cravings among participants w...
|
|
|
Announcement
In a notable development concerning the biotechnology sector, Intellia Therapeutics, Inc. (NASDAQ: NTLA) is facing a class action securities lawsuit as announced by the law firm Levi and Korsinsky, LLP. The lawsuit, filed in a New York court, raises concerns about potential violations of securities laws by the company, prompting investors to rethink their...
|
|
|
Stock Market Announcement
Intellia Therapeutics: Strategic Inducement Grants Fuel Growth in CRISPR Gene Editing InnovationIntellia Therapeutics, Inc. (NASDAQ: NTLA), a pioneer in gene editing through CRISPR-based therapies, continues to bolster its workforce by granting inducements to new hires. The company awarded inducement grants under the Nasdaq Listing Rule 5635(c)(4) as a p...
|
|
|
Product Service News
ImmuCell Marks a Milestone with Investigational Product Launch: Re-Tain Set to Transform Animal Health Industry In the bustling heart of Portland, Maine, a promising shift is underway in the realm of animal health. ImmuCell Corporation (Nasdaq: ICCC), an innovative player dedicated to enhancing dairy and beef cattle health, has announced the initiation of...
|
|
|
Merger and Acquisition
BEDFORD, Mass. April 1, 2025 ? In a significant move projected to reshape the landscape of radiopharmaceuticals, Lantheus Holdings, Inc. (NASDAQ: LNTH), has finalized its acquisition of Evergreen Theragnostics, Inc. a clinical-stage company specializing in innovative diagnostic and therapeutic radiopharmaceuticals. This transaction, first announced on Jan...
|
|
|
Announcement
In the fast-paced world of biotechnology, the importance of protecting investor interests cannot be overstated. As the landscape shifts with breakthrough research and corporate developments, the cautionary tales of missteps and missed opportunities proliferate. In this regard, Rosen Law Firm, a respected global investor rights law firm, is sounding the al...
|
|
|
Announcement
In a landscape where innovative medical therapeutics often drive market excitement, Intellia Therapeutics, Inc. (NASDAQ: NTLA) is currently navigating both financial headwinds and potential legal challenges. Rosen Law Firm, a prominent global investor rights law firm, has recently issued a reminder to those who purchased Intellia securities between July 3...
|
|
|
Announcement
In the world of investment, legal challenges are often indicative of deeper systemic issues within corporations. Recently, Bragar Eagel and Squire, P.C. a heavyweight in shareholder rights legal action, announced class action lawsuits against several big-name corporations FMC Corporation, Elastic N.V. Intellia Therapeutics, and Merck and Co. Inc. This sur...
|
|
|
Business Update
TNF Pharmaceuticals Set to Showcase Promising Advances in Autoimmune Therapies During Upcoming Investor ConferenceIn a significant development for investors and stakeholders in the biopharmaceutical sector, TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) has announced an upcoming investor conference call and webcast scheduled for March 6, 2025, at 4:30 PM ET. T...
|
|
|
Management Changes
In a significant development poised to shape the future trajectory of corporate governance and risk management, Myriad Genetics has announced a transition in its senior leadership. Effective April 30, 2025, Sam Raha will assume the role of Chief Executive Officer, while Mark S. Verratti steps in as Chief Operating Officer. This strategic shift highlights ...
|
|
|
Stock Market Announcement
Intellia Therapeutics, Inc. (NASDAQ: NTLA), headquartered in Cambridge, Massachusetts, continues to solidify its position as a leader in the clinical-stage gene editing sector. The company, renowned for its cutting-edge CRISPR-based therapies, recently announced an intriguing development on February 4, 2025. Intellia has awarded inducement grants to three...
|
|
|
Merger and Acquisition
In a significant advance for the field of radiopharmaceuticals, Lantheus Holdings, a leader in medical imaging and diagnostics, has announced its intent to acquire Evergreen Theragnostics in a move designed to bolster its capabilities in scalable manufacturing and end-to-end clinical development. This strategic acquisition, coupled with the recent launch ...
|
|
|
Business Update
In the rapidly evolving landscape of governance, risk, and compliance (GRC), Diligent continues to position itself as a key player in providing advanced software-as-a-service (SaaS) solutions. Recently highlighted in SandP Global Market Insights, Diligent is recognized for its contribution to enhancing the efficiency and effectiveness of corporate governa...
|
|
|
Stock Market Announcement
Myriad Genetics Unveils Promising Financial Guidance for 2025 Amid Strategic InnovationsIn a recent press release, Myriad Genetics, a leading molecular diagnostic company, showcased its preliminary financial outcomes for the fourth quarter and full fiscal year 2024 while setting the stage with optimistic guidance for 2025. This announcement underscores My...
|
|
|
Merger and Acquisition
Lantheus Holdings Strengthens Market Position with Strategic Developments in Alzheimer?s DiagnosticsIn the fast-evolving landscape of medical diagnostics, Lantheus Holdings Inc. (NASDAQ: LNTH) is making significant strides to enhance its growth trajectory, particularly within the Alzheimer s disease segment. Recently, the company has been in the spotlight...
|
|
|
Management Announcement
Intellia Therapeutics Charts Ambitious Course for 2025: Prioritizing Late-Stage Programs and Strengthening Talent for CRISPR InnovationIn a bold move signaling its commitment to advancing groundbreaking gene editing technologies, Intellia Therapeutics, Inc. (NASDAQ: NTLA), a pioneer in CRISPR-based therapies, has unveiled its strategic priorities and key ...
|
|
|
Shares
In a notable development for shareholders of Intellia Therapeutics, Inc. (NASDAQ: NTLA), the company announced the awarding of inducement grants to three new employees as part of its 2024 Inducement Plan on January 1, 2025. This strategic move reflects Intellia?s commitment to bolstering its workforce with top talent, which is critical for a clinical-stag...
|
|
|
Product Service News
In an evolving landscape of prostate cancer diagnostics and treatment, Myriad Genetics Prolaris test stands out as a significant advancement, recently classified as an advanced tool by the National Comprehensive Cancer Network (NCCN) in their Prostate Cancer Guidelines. This endorsement from such a prestigious and authoritative body underscores the trans...
|
|
|
Business Update
In a significant development that could reshape the treatment landscape for sarcopenia a prevalent condition characterized by muscle loss and frailty TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) recently unveiled promising results from a Phase 2a clinical trial of its lead drug candidate, MYMD-1 (isomyosamine). The findings were presented at a prestigious int...
|
|
|
Financing Agreement
Trinity Biotechns Strategic Financial Maneuvers and Manufacturing Transition: Paving the Way for Market LeadershipIn a bold move to enhance operational efficiency and fortify its financial standing, Trinity Biotech plc (Nasdaq: TRIB), a biotechnology company based in Dublin, has taken significant steps towards executing its Comprehensive Transformation P...
|
|
|
Clinical Study
Celldex Therapeutics Advances Barzolvolimab Research with Promising Results in Atopic Dermatitis and Urticaria HAMPTON, N.J. Dec. 19, 2024 In a significant stride for dermatological therapeutics, Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced the initiation of a Phase 2 study for barzolvolimab, aimed at addressing the debilitating effects of atopic ...
|
|
|
Clinical Study
Trinity Biotech plc, a biotechnology company based in Dublin, Ireland, has received timely approval from the World Health Organization (WHO) to initiate offshore manufacturing for its TrinScreen HIV and Uni-Gold HIV diagnostic tests. This development aligns with the company?s Comprehensive Transformation Plan and marks a significant step in enhancing the ...
|
|
|
Shares
Intellia Therapeutics Amplifies Talent Acquisition with Strategic Inducement GrantsIn the rapidly evolving landscape of biotechnology, talent acquisition is not just a routine human resources operation; it is a strategic imperative that can shape the trajectory of a company. This is particularly pertinent in the case of Intellia Therapeutics, Inc. (NASDAQ...
|
|
|
Clinical Study
: Celldex Therapeutics, Inc. has announced the commencement of a Phase 1a clinical trial for CDX-622, a bispecific antibody aimed at addressing chronic inflammatory diseases. This study represents an important step in evaluating the therapeutic potential of targeting key immunological pathways involved in inflammation. On November 20, 2024, Celldex Ther...
|
|
|
Stock Market Announcement
Lantheus Holdings Strategic Share Repurchase: A $250 Million Commitment to Growth and Shareholder ValueIn a strategic move aimed at enhancing shareholder value and reflecting confidence in its business model, Lantheus Holdings, Inc. (NASDAQ: LNTH) has announced a $250 million share repurchase program authorized by its board of directors. The announcemen...
|
|
|
Product Service News
In a groundbreaking advancement that could redefine the future of genetic medicine, Intellia Therapeutics, Inc., a prominent leader in CRISPR-based therapies, has recently reported promising results from its Phase 1 clinical study of nexiguran ziclumeran, also referred to as NTLA-2001. This novel therapy marks a significant step toward a one-time treatmen...
|
|
|
Management Announcement
Lantheus Applauds CMS 2025 Payment Rule Enhancements for Diagnostic Radiopharmaceuticals: PYLARIFY Positioned for Continued SuccessLantheus Holdings, Inc., a key player in the radiopharmaceutical industry, has recently expressed its commendation for the Centers for Medicare and Medicaid Services (CMS) decision to enhance payment structures related to spe...
|
|
|
Stock Market Announcement
Biomerica Granted 180-Day Extension by Nasdaq to Regain Listing Compliance Amidst Product ExpansionBiomerica, Inc. (Nasdaq: BMRA), a prominent player in the medical diagnostics industry, has been given a lifeline by the Nasdaq Stock Market LLC with a 180-day extension to comply with its listing requirements. The announcement came on November 7, 2024, prov...
|
|
|
Shares
Trinity Biotech plc, a commercial-stage biotechnology firm with a focus on human diagnostics and diabetes management, has announced a significant regain of compliance with Nasdaq listing requirements. On November 6, 2024, the company received written confirmation from the Nasdaq Stock Market LLC (Nasdaq) that it has successfully met the minimum market val...
|
|
|
|
|
|
